Filing Flows

Filing Flows › Zevra Therapeutics (ZVRA) › Next earnings date

Zevra Therapeutics (ZVRA) earnings: beat the estimate

Zevra Therapeutics (ZVRA) reported on Nov 3, 2026 and beat the EPS estimate: $0.23 against $0.17 (+35.3%). Revenue was $37.8M for Q3 2026, +45% year over year. It beat the EPS estimate in 100% of the quarters on record.

Last result+35.3% vs estimate
Beat rate100%

The last report

Zevra Therapeutics reported revenue of $37.8M for the third quarter 2026 (+45% Y/Y), net earnings $19.2M. How it makes money → · Every quarter →

Zevra Therapeutics: EPS against the estimate, last 5 reportsZevra Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.02−$0.01Nov 25$0.04$0.19Mar 26$0.08$0.18May 26$0.18$0.25Aug 26$0.17$0.23Nov 26
Latest (Nov 26): Estimate $0.17, Reported $0.23.
ZVRA: the stock's move on each reportZVRA: the stock's move on each reportAug 5, 2026+12.9%May 6, 2026+3.7%Mar 9, 2026+23.2%Nov 5, 2025-7.2%

Zevra Therapeutics' latest quarter

Zevra Therapeutics, Q3 2026: revenue $37.8M (+45% year over year), operating margin 30.7%, net earnings $19.2M, operating cash flow $10.0M. The chart follows the revenue to costs, profit and cash.

Questions

Did Zevra Therapeutics beat earnings?

Zevra Therapeutics (ZVRA) reported on Nov 3, 2026 and beat the EPS estimate: $0.23 against $0.17 (+35.3%).

When does ZVRA report earnings?

The next date is not set yet.

Does Zevra Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 100% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.